Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia

From Children's Hospital of Philadelphia (S.A.G., D.B., R.A., S.R.R., D.T.T., B.H., J.F.W.)
New England Journal of Medicine (Impact Factor: 55.87). 03/2013; 368(16). DOI: 10.1056/NEJMoa1215134
Source: PubMed

ABSTRACT Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established whether chimeric antigen receptor T cells have clinical activity in acute lymphoblastic leukemia (ALL). Two children with relapsed and refractory pre-B-cell ALL received infusions of T cells transduced with anti-CD19 antibody and a T-cell signaling molecule (CTL019 chimeric antigen receptor T cells), at a dose of 1.4×10(6) to 1.2×10(7) CTL019 cells per kilogram of body weight. In both patients, CTL019 T cells expanded to a level that was more than 1000 times as high as the initial engraftment level, and the cells were identified in bone marrow. In addition, the chimeric antigen receptor T cells were observed in the cerebrospinal fluid (CSF), where they persisted at high levels for at least 6 months. Eight grade 3 or 4 adverse events were noted. The cytokine-release syndrome and B-cell aplasia developed in both patients. In one child, the cytokine-release syndrome was severe; cytokine blockade with etanercept and tocilizumab was effective in reversing the syndrome and did not prevent expansion of chimeric antigen receptor T cells or reduce antileukemic efficacy. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment. The other patient had a relapse, with blast cells that no longer expressed CD19, approximately 2 months after treatment. Chimeric antigen receptor-modified T cells are capable of killing even aggressive, treatment-refractory acute leukemia cells in vivo. The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL.

27 Reads
  • Source
    • "Patients' T cells, easily accessible in peripheral blood, can be genetically instructed to target tumors by transduction of receptors for antigen, utilizing either the physiological TCR (Ho et al., 2003; Stone and Kranz, 2013) or synthetic receptors now known as CARs (Sadelain et al., 2009). Both approaches have shown clinical successes, particularly in melanoma (Robbins et al., 2011), targeting NY- ESO1 (Chen et al., 1997), and in acute lymphoblastic leukemia, (Brentjens et al., 2013; Grupp et al., 2013; Davila et al., 2014; Lee et al., 2015; Maude et al., 2014), targeting CD19 (Brentjens et al., 2003). CARs are artificial, composite receptors for antigen that integrate principles of B cell and T cell antigen recognition (Figure 3A). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent advances in cancer immunotherapy have directly built on 50 years of fundamental and technological advances that made checkpoint blockade and T cell engineering possible. In this review, we intend to show that research, not specifically designed to bring relief or cure to any particular disease, can, when creatively exploited, lead to spectacular results in the management of cancer. The discovery of thymus immune function, T cells, and immune surveillance bore the seeds for today's targeted immune interventions and chimeric antigen receptors. Copyright © 2015 Elsevier Inc. All rights reserved.
    Cancer cell 04/2015; 27(4). DOI:10.1016/j.ccell.2015.03.007 · 23.52 Impact Factor
  • Source
    • "The transferred cells may be ex vivo expanded tumor infiltrating lymphocytes (TIL) [2], transgenic T-cell receptor (TCR) T cells [3] [4], or chimeric antigen receptor (CAR) T cells [5e7]. In particular, CAR T cells have shown some promising activity with complete responses observed in patients with leukemia [8] [9] and neuroblastoma [10]. However, despite these encouraging early clinical data, factors that influence CAR T-cell persistence and anti-tumor activity still require optimization. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chimeric antigen receptor (CAR) T cells are a novel immunotherapy for cancer. To achieve anti-tumor efficacy, these cells must survive, expand, and persist after infusion into patients, functions that are reportedly best achieved by cells with a stem or central-memory rather than effector-memory phenotype. We have developed third-generation CAR T cells specific for the tumor-associated antigen GD2 for use in a phase I clinical trial. We investigated the optimal cell culture conditions for CAR T-cell production, and here we describe the relative effects of 3 activation and cytokine conditions on CAR T-cell expansion, effector function and phenotype. Peripheral blood mononuclear cells were activated by anti-CD3 and anti-CD28 or anti-CD3 and Retronectin. Activated cells were transduced with the CAR-encoding retroviral vector and expanded in either interleukin (IL)-2 or IL-7 and IL-15. Immune phenotype and expansion were tracked throughout the culture, and transduction efficiency, and subsequent GD2-specific effector functions were evaluated by flow cytometry and cytotoxic T lymphocytes assay. CD3/Retronectin stimulation with IL-2 resulted in poorer activation, expansion and Th1 cytokine secretion of CAR T cells than CD3/CD28 stimulation with either IL-2 or IL-7 and IL-15. However, CAR T cells cultured in CD3/CD28/IL7/IL-15 and CD3/Retronectin/IL-2 had superior cytotoxic T lymphocyte activity and a more stem-like phenotype. The combination of CD3 and CD28 with IL-7 and IL-15 gave the best balance of CAR T-cell expansion and potent GD2-specific effector functions while retaining a stem/memory phenotype, and these growth conditions will therefore be used to manufacture CAR T cells for our phase I clinical trial. Copyright © 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.
    Cytotherapy 01/2015; 17(4). DOI:10.1016/j.jcyt.2014.12.002 · 3.29 Impact Factor
  • Source
    • "ells with enhanced receptor - mediated function , such as cytokine ( IFNc ) production . Importantly , one might question the desirability of augmented cytokine production given the reported cytokine release syndromes in recent adoptive CD19 CAR T cell therapy trials ( Kalos et al . , 2011 ; Kochenderfer et al . , 2012 ; Brentjens et al . , 2013 ; Grupp et al . , 2013 ) . However , a cytokine storm generally occurred several days to weeks after infusion of the T cells as a con - sequence of on - target T cell activation in patients with rela - tively bulky disease and can potentially be considered as a hallmark of therapy effectivity Yet , clinical surveillance is critical to control such a side effe"
    [Show abstract] [Hide abstract]
    ABSTRACT: Therapy with autologous T cells that have been gene-engineered to express chimeric antigen receptors (CAR) or T cell receptors (TCR) provides a feasible and broadly applicable treatment for cancer patients. In a clinical study in advanced renal cell carcinoma (RCC) patients with CAR T cells specific for Carbonic Anhydrase IX (CAIX) we observed toxicities which (most likely) indicated in vivo function of CAR T cells as well as low T cell persistence and clinical response rates. The latter observations were confirmed by later clinical trials in other solid tumor types and other gene-modified T cells. To improve the efficacy of T cell therapy, we have re-defined in vitro conditions to generate T cells with young phenotype, a key correlate with clinical outcome. For their impact on gene modified T cell phenotype and function, we have tested various anti-CD3/CD28 mAb-based T cell activation and expansion conditions as well as several cytokines prior to and/or post gene transfer using two different receptors: CAIX CAR and MAGE-C2(ALK)/HLA-A2 TCR. In a total set of 16 healthy donors, we observed that T cell activation with soluble anti-CD3/CD28 mAbs in the presence of both IL15 and IL21 prior to TCR gene transfer resulted in enhanced proportions of gene-modified T cells with a preferred in vitro phenotype and better function. T cells generated according to these processing methods demonstrated enhanced binding of pMHC, and an enhanced proportion of CD8+,CD27+,CD62L+,CD45RA+ T cells. These new conditions will be translated into a GMP protocol in preparation of a clinical adoptive therapy trial to treat patients with MAGE-C2-positive tumors.
    Human Gene Therapy Methods 11/2014; 25(6). DOI:10.1089/hgtb.2014.051 · 2.44 Impact Factor
Show more


27 Reads
Available from